<DOC>
	<DOCNO>NCT01836120</DOCNO>
	<brief_summary>A study Raltitrexed plus Docetaxel versus Docetaxel second-line chemotherapy subject Gastric Cancer.The purpose study compare activity Raltitrexed plus Docetaxel versus Docetaxel second-line chemotherapy subject gastric carcinoma estimate progression free survival ( PFS ) treatment arm .</brief_summary>
	<brief_title>A Study Raltitrexed Plus Docetaxel Versus Docetaxel Second-line Chemotherapy Subjects With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>1 . Signed informed consent form 2 . Performance Status Eastern Cooperative Oncology Group ( ECOG ) 02 ; 3 . Histologically cytologically confirm gastric cancer ; 4 . The firstline chemotherapy failure ( require contain 5fluorouracil ) 5 . At least one measurable disease ( accord RECIST , Response Evaluation Criteria Solid Tumors ) 6 . Life expectancy least 3 month ; 1 . Received prior treatment include Raltitrexed ; 2 . Active uncontrolled infection ; 3 . Concurrent treatment investigational agent participation another therapeutic clinical trial ; 4 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>second-line chemotherapy</keyword>
	<keyword>Raltitrexed</keyword>
</DOC>